Skip to menu Skip to content Skip to footer

2017

Conference Publication

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

Tobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

2017

Journal Article

The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma

Ladwa, Rahul and Atkinson, Victoria (2017). The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma. Melanoma Research, 27 (2), 168-170. doi: 10.1097/CMR.0000000000000336

The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma

2017

Conference Publication

Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent Immunotherapy

Caldwell, Reece, Mason, Robert and Atkinson, Victoria (2017). Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent Immunotherapy. COSA's 44th Annual Scientific Meeting, Immunotherapy: Molecules and Mountains, Sydney, NSW Australia, 13–15 November 2017. Hoboken, NJ United States: Wiley.

Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent Immunotherapy

2016

Journal Article

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists

Atkinson, Victoria, Long, Georgina V., Menzies, Alexander M., McArthur, Grant, Carlino, Matteo S., Millward, Michael, Roberts-Thomson, Rachel, Brady, Benjamin, Kefford, Richard, Haydon, Andrew and Cebon, Jonathan (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists. Asia Pacific Journal of Clinical Oncology, 12 (S7), 5-12. doi: 10.1111/ajco.12656

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists

2016

Conference Publication

Complete responders to anti-PD1 antibodies. What happens when we stop?

Atkinson, V. G. and Ladwa, R. (2016). Complete responders to anti-PD1 antibodies. What happens when we stop?. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.11

Complete responders to anti-PD1 antibodies. What happens when we stop?

2016

Conference Publication

Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access program

Ladwa, R., Andelkovic, V. and Atkinson, V. (2016). Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access program. Implementation + Innovation in Immunotherapy, Gold Coast, QLD, Australia, 3-5 August 2016. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12542

Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access program

2015

Journal Article

Sentinel node biopsy for melanoma: The medical oncology perspective

Menzies, Alexander M., Atkinson, Victoria G., Brown, Michael P., Carlino, Matteo S., Cebon, Jonathan, Guminski, Alexander, Kefford, Richard F., Long, Georgina V., McArthur, Grant, McNeil, Catriona M., Millward, Michael and Sandhu, Shahneen (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44 (12), 875-876.

Sentinel node biopsy for melanoma: The medical oncology perspective

2015

Conference Publication

Pembrolizumab for metastatic melanoma - one year results of named patient access program

Atkinson, Victoria G., Andelkovic, Vladimir and Gunawan, Benjamin (2015). Pembrolizumab for metastatic melanoma - one year results of named patient access program. COSA’s 42nd Annual Scientific Meeting. Rare Cancers: Common Goals, Hobart, TAS, Australia, 17-19 November 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12432_2

Pembrolizumab for metastatic melanoma - one year results of named patient access program

2015

Journal Article

Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix

Sparks, David S., Morris, Bradley, Xu, Wen, Fulton, Jessica, Atkinson, Victoria, Meade, Brian and Lutton, Nicholas (2015). Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix. International Surgery, 100 (1), 21-28. doi: 10.9738/INTSURG-D-14-00089.1

Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix

2015

Journal Article

Nivolumab in Previously Untreated Melanoma without a BRAF mutation

Robert, Caroline, Long, Georgina, Brady, Benjamin, Dutriaux, Caroline, Miao, Michele, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinsk-Warzocha, Ewa, Savage, Kerry, Hernberg, Michaela, Lebbe, Cleste, Charles, Julie, Mihalcioiu, Caitlin, Chiarion-Sileni, Vanna, Mauch, Conrelia, Cognetti, Francesco, Arance, Ana, Schmidt, Kenrik, Schadendorf, Dirk, Gogas, Helen, Lundgren-Erikkson, Lotta, Horak, Christine, Sharkey, Brian, Waxman, Ian, Atkinson, Victoria and Ascierto, Paolo (2015). Nivolumab in Previously Untreated Melanoma without a BRAF mutation. The New England Journal of Medicine, 372 (4), 320-330. doi: 10.1056/NEJMoa1412082

Nivolumab in Previously Untreated Melanoma without a BRAF mutation

2015

Journal Article

Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.

Gorayski, Peter, Dzienis, Marcin, Foote, Matthew, Atkinson, Victoria, Burmeister, Elizabeth and Burmeister, Bryan (2015). Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.. Asia Pacific Journal of Oncology, 13 (2), E117-E123. doi: 10.1111/ajco.12345

Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.

2015

Conference Publication

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

Privthviraj, Prashanth, McArthur, Grant, Atkinson, Victoria, Parente, Phillip, Andrews, Miles Cameron, Parakh, Sagun, Cebon, Jonathon and Klein, Oliver (2015). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

2015

Conference Publication

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.

Larkin, James M. G., Yan, Yibing, McArthur, Grant A., Ascierto, Paolo Antonio, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev V., Stroyakovskiy, Daniil, Thomas, Luc, De La Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Wongchenko, Matthew, Rooney, Isabelle Anne, Chang, Ilsung, Hack, Stephen Paul, Dreno, Brigitte and Ribas, Antoni (2015). Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.. American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology.

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.

2015

Conference Publication

Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma(MEL): Results of a Phase III study (Checkmate066)

Long, Georgina V., Atkinson, Victoria, Ascierto, Paolo Antion, Robert, Caroline, Hassel, Jessica Cecile, Rutkowski, Piotr, Savage, Kerry, Taylor, Fiona, Coon, Cheryl, Gilloteau, Isabelle, Dasanti, Homa, Waxman, Ian and Pickar Abernethy, Amy (2015). Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma(MEL): Results of a Phase III study (Checkmate066). American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology.

Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma(MEL): Results of a Phase III study (Checkmate066)

2014

Journal Article

Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma

Larkin, James, Ascierto, Paolo, Dren, Brigette, Atkinson, Victoria, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Sovak, Mika, Chang, Ilsung, Choong, Nicholas, Hack, Stephen, McArthur, Grant A. and Ribas, Antoni (2014). Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma. The New England Journal of Medicine, 371 (20), 1867-1876. doi: 10.1056/NEJMoa1408868

Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma

2014

Journal Article

BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib

McClenahan, Phil, Lin, Lynlee L., Tan, Jean-Marie, Flewell-Smith, Ross, Schaider, Helmut, Jagirdar, Kasturee, Atkinson, Victoria, Lambie, Duncan, Prow, Tarl W., Sturm, Richard A. and Soyer, Peter (2014). BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib. JAMA Dermatology, 150 (10), 1079-1082. doi: 10.1001/jamadermatol.2014.436

BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib

2014

Conference Publication

Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study

Martin-Algarra, Salvador, Cebon, Jonathan, Neyns, Bart, Brown, Ewan, Puertolas, Teresa, Garcia, Yolanda, Atkinson, Victoria, Crown, John, Lau, Mike, Dalland, Lindi, Stein, Dara, Payne, Krista, Aktan, Gursel, Jobanputra, Minesh, Queirolo, Paola and Millward, Michael (2014). Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study. Society for Melanoma Research, Zurich, Switzerland, November 2014. Hoboken, NJ United States: Wiley-Blackwell Publishing. doi: 10.1111/pcmr.12317

Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study

2014

Journal Article

Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review

Dzienis, Marcin and Atkinson, Victoria (2014). Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review. Melanoma Research, 24 (4), 349-353. doi: 10.1097/CMR.0000000000000068

Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review

2013

Conference Publication

Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013

Dzienis, Marcin Radoslaw and Atkinson, Victoria (2013). Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013. American Society of Clinical Oncology Annual Meeting, 2013, Chicago, IL United States, 31 May - 3 June 2013. Alexandria, VA United States: American Society of Clinical Oncology.

Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013

2013

Conference Publication

Single institution experience of Hyperthermic Intraperitoneal Chemotherapy

Xu, Wen, Sparks, David, Atkinson, Victoria, Joubert, Warren, Lutton, Nicholas and Meade, Brian (2013). Single institution experience of Hyperthermic Intraperitoneal Chemotherapy. Annual Scientific Meeting of Medical Oncology Group of Australia, Melbourme, Australia, August 2013.

Single institution experience of Hyperthermic Intraperitoneal Chemotherapy